

I. Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (cancelled).
2. (currently amended): A method for reducing an oxytocin-mediated action in a subject comprising administering to the subject an amount of thiazolidinedione effective to reduce the oxytocin-mediated action in the subject, wherein the oxytocin-mediated action is induction of labor in a pregnant subject, induction of uterine cramps, induction of milk letdown, or induction of prostaglandin release.
3. (original): The method of claim 2, wherein the oxytocin-mediated action is induction of labor in a pregnant subject.
4. (original): The method of claim 2, wherein the oxytocin-mediated action is induction of uterine cramps.
5. (original): The method of claim 2, wherein the oxytocin-mediated action is induction of milk letdown.
6. (original): The method of claim 2, wherein the oxytocin-mediated action is induction of prostaglandin release.
7. (original): The method of claim 2, wherein the subject is a mammal.
8. (currently amended): The method of claim 2, wherein the thiazolidinedione ~~comprises~~ is troglitazone.

9. (currently amended): The method of claim 2, wherein the thiazolidinedione ~~comprises~~ is pioglitazone, BRL49653, or a compound related to troglitazone.
10. (original): The method of claim 2, wherein the thiazolidinedione is dispersed in a pharmacologically acceptable form.
11. (original): The method of claim 10, wherein said thiazolidinedione is administered locally.
12. (original): The method of claim 10, wherein said thiazolidinedione is administered parenterally.
13. (original): The method of claim 12, wherein said thiazolidinedione is administered intravenously.
14. (original): The method of claim 11, wherein the thiazolidinedione is administered intravaginally.
15. (currently amended): The method of claim ~~[[3]]~~ 2, further comprising administering a tocolytic agent.
16. (original): The method of claim 15, wherein said tocolytic agent comprises a beta-mimetic, magnesium sulfate, a prostaglandin inhibitor, or a calcium-blocking agent.
17. (original): The method of claim 16, wherein the prostaglandin inhibitor is indomethacin.
18. (original): The method of claim 17, wherein the calcium-blocking agent is nifedipine.
19. (original): The method of claim 15, wherein the tocolytic agent and thiazolidinedione are administered simultaneously.

Claims 20-21 (cancelled).